- Home
- SNTI vs IMNN Comparison
SNTI vs IMNN Comparison
Compare SNTI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- IMNN
- Stock Information
- Founded
- SNTI 2016
- IMNN 1982
- Country
- SNTI United States
- IMNN United States
- Employees
- SNTI N/A
- IMNN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- IMNN Health Care
- Exchange
- SNTI Nasdaq
- IMNN Nasdaq
- Market Cap
- SNTI 18.2M
- IMNN 12.2M
- IPO Year
- SNTI N/A
- IMNN 1985
- Fundamental
- Price
- SNTI $3.97
- IMNN $0.83
- Analyst Decision
- SNTI Strong Buy
- IMNN Strong Buy
- Analyst Count
- SNTI 1
- IMNN 2
- Target Price
- SNTI $12.00
- IMNN $20.50
- AVG Volume (30 Days)
- SNTI 7.2M
- IMNN 395.1K
- Earning Date
- SNTI 11-14-2024
- IMNN 11-07-2024
- Dividend Yield
- SNTI N/A
- IMNN N/A
- EPS Growth
- SNTI N/A
- IMNN N/A
- EPS
- SNTI N/A
- IMNN N/A
- Revenue
- SNTI N/A
- IMNN N/A
- Revenue This Year
- SNTI $254.47
- IMNN N/A
- Revenue Next Year
- SNTI $169.66
- IMNN N/A
- P/E Ratio
- SNTI N/A
- IMNN N/A
- Revenue Growth
- SNTI N/A
- IMNN N/A
- 52 Week Low
- SNTI $1.52
- IMNN $0.48
- 52 Week High
- SNTI $16.94
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- SNTI 47.37
- IMNN 47.27
- Support Level
- SNTI $3.60
- IMNN $0.80
- Resistance Level
- SNTI $5.96
- IMNN $0.88
- Average True Range (ATR)
- SNTI 1.02
- IMNN 0.05
- MACD
- SNTI -0.29
- IMNN 0.00
- Stochastic Oscillator
- SNTI 5.74
- IMNN 25.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.